AtaiBeckley completes enrollment in Phase 2b depression trial

July 6, 2026 6:00 AM

AtaiBeckley Inc. (NASDAQ: ATAI) announced it has dosed the last patient in its Elumina Phase 2b clinical trial evaluating VLS-01 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found